Interview: The Global Trade in Reproduction
By Carmel Shalev,
BioEdge
| 09. 20. 2014
Untitled Document
Dr Carmel Shalev, of Israel’s Haifa University, is organising a session on helpful and harmful practices in the ethics and regulation of inter-country medically assisted reproduction in Jerusalem in January. It will be part of the 10th World Conference on Bioethics, Medical Ethics and Health Law.
Untitled Document
BioEdge: “inter-country medically assisted reproduction” – do you basically mean a market for surrogate mothers and babies?
Shalev: Yes, that’s a major concern, but not the only one. For example, there is also a market in inter-country egg donations. The problem is that there have been too many cases of harm to children and to the third-party women who agree to take part in reproductive collaborations for the benefit of others, as genetic mothers (egg providers) and birth mothers (surrogate mothers).
What are the “products” in the market?
The products in surrogacy are children. In other practices the products are human gametes (eggs and sperm) and embryos (fertilised eggs). Unfortunately, women are being used as a means of production, and objectified in the process.
How much has...
Related Articles
By Judd Boaz and Elise Kinsella, ABC News | 03.17.2026
By Gabriele Pichlhofer and Tino Plümecke, Guest Contributors
| 03.25.2026
A German translation of this interview will be published in May 2026 in the German GID MAGAZIN, which focuses on the market for reproductive technologies. For more information, visit: Gen-ethisches Netzwerk
Egg donation is currently prohibited in Germany and Switzerland, but both countries have been debating its legalization for years. In Switzerland, a legal framework is currently being developed, with a first draft expected by the end of the year. Yet the debate rarely draws on scientific evidence. Instead...
By Charles Pulliam-Moore, The Verge | 03.21.2026
Like many people, director Valerie Veatch was intrigued when OpenAI first released its Sora text-to-video generative AI model to the public in 2024. Though she didn’t fully understand the technology, she was curious about what it could do, and she...
By Ritsuko Kawai, Wired | 03.14.2026
On March 6, Japan’s Ministry of Health, Labor and Welfare officially granted conditional and time-limited marketing authorization to two regenerative medical products derived from reprogrammed iPS cells, marking exactly 20 years since the creation of mouse iPS cells.These will...